Cargando…

Correlating drug–target kinetics and in vivo pharmacodynamics: long residence time inhibitors of the FabI enoyl-ACP reductase

Drug–target kinetics enable time-dependent changes in target engagement to be quantified as a function of drug concentration. When coupled to drug pharmacokinetics (PK), drug–target kinetics can thus be used to predict in vivo pharmacodynamics (PD). Previously we described a mechanistic PK/PD model...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daryaee, Fereidoon, Chang, Andrew, Schiebel, Johannes, Lu, Yang, Zhang, Zhuo, Kapilashrami, Kanishk, Walker, Stephen G., Kisker, Caroline, Sotriffer, Christoph A., Fisher, Stewart L., Tonge, Peter J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Royal Society of Chemistry 2016
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988406/ https://www.ncbi.nlm.nih.gov/pubmed/27547299 http://dx.doi.org/10.1039/c6sc01000h

Ejemplares similares

Pharmacophore and Molecular Docking Guided 3D-QSAR Study of Bacterial Enoyl-ACP Reductase (FabI) Inhibitors
por: Lu, Xiaoyun, et al.
Publicado: (2012)

Determination of the Crystal Structure and Active Residues of FabV, the Enoyl-ACP Reductase from Xanthomonas oryzae
por: Li, He, et al.
Publicado: (2011)

Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression
por: Grandgirard, Denis, et al.
Publicado: (2015)

A Structural and Energetic Model for the Slow-Onset Inhibition of the Mycobacterium tuberculosis Enoyl-ACP Reductase InhA
por: Li, Huei-Jiun, et al.
Publicado: (2014)

Bacterial Enoyl-Reductases: The Ever-Growing List of Fabs, Their Mechanisms and Inhibition
por: Hopf, Fernanda S. M., et al.
Publicado: (2022)

In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
por: Dureja, Chetna, et al.
Publicado: (2023)

Pyrrolyl Pyrazoline Carbaldehydes as Enoyl-ACP Reductase Inhibitors: Design, Synthesis and Antitubercular Activity
por: Dixit, Sheshagiri R., et al.
Publicado: (2017)

Unsaturated fatty acid synthesis in Enterococcus faecalis requires a specific enoyl‐ACP reductase
por: Dong, Huijuan, et al.
Publicado: (2022)

Structure-based identification of novel inhibitors targeting the enoyl-ACP reductase enzyme of Acinetobacter baumannii
por: Khan, Shama, et al.
Publicado: (2023)

Nonactive-Site Mutations in S. aureus FabI That Induce Triclosan Resistance
por: Demissie, Robel, et al.
Publicado: (2020)

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model
por: Banevicius, Mary A, et al.
Publicado: (2013)

Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics
por: Tsuji, Brian T, et al.
Publicado: (2013)

QSAR and Molecular Docking Studies of Oxadiazole-Ligated Pyrrole Derivatives as Enoyl-ACP (CoA) Reductase Inhibitors
por: Asgaonkar, Kalyani D., et al.
Publicado: (2014)

In Silico Repositioning of Cannabigerol as a Novel Inhibitor of the Enoyl Acyl Carrier Protein (ACP) Reductase (InhA)
por: Pinzi, Luca, et al.
Publicado: (2019)

Functional Characterization of Triclosan-Resistant Enoyl-acyl-carrier Protein Reductase (FabV) in Pseudomonas aeruginosa
por: Huang, Yong-Heng, et al.
Publicado: (2016)

Molecular Modelling Study and Antibacterial Evaluation of Diphenylmethane Derivatives as Potential FabI Inhibitors
por: Hasan, Shaima, et al.
Publicado: (2023)

Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme
por: Martinelli, Leonardo K. B., et al.
Publicado: (2017)

Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens
por: Parker, Erica N., et al.
Publicado: (2019)

1233. Identification of Novel Inhibitors of Clostridioides difficile Enoyl-Reductase II (FabK) by High-Throughput Virtual and Experimental Screening
por: Wahrmund, Rebecca D, et al.
Publicado: (2020)

Staphylococcus aureus but not Listeria monocytogenes adapt to triclosan and adaptation correlates with increased fabI expression and agr deficiency
por: Nielsen, Lene Nørby, et al.
Publicado: (2013)

Meleagrin, a New FabI Inhibitor from Penicillium chryosogenum with at Least One Additional Mode of Action
por: Zheng, Chang Ji, et al.
Publicado: (2013)

A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy
por: Daryaee, Fereidoon, et al.
Publicado: (2017)

Observed crowding effects on Mycobacterium tuberculosis 2-trans-enoyl-ACP (CoA) reductase enzyme activity are not due to excluded volume only
por: Rotta, Mariane, et al.
Publicado: (2017)

Drug-likeness prediction of designed analogues of isoniazid standard targeting FabI enzyme regulation from P. falciparum
por: Pandey, Anil Kumar, et al.
Publicado: (2019)

Aqueous Molecular Dynamics Simulations of the M. tuberculosis Enoyl-ACP Reductase-NADH System and Its Complex with a Substrate Mimic or Diphenyl Ethers Inhibitors
por: da Silva Lima, Camilo Henrique, et al.
Publicado: (2015)

Synthesis and Antimicrobial Activity Screening of Piperazines Bearing N,N′-Bis(1,3,4-thiadiazole) Moiety as Probable Enoyl-ACP Reductase Inhibitors
por: Omar, Alaa Z., et al.
Publicado: (2022)

A novel 3‐oxoacyl‐ACP reductase (FabG3) is involved in the xanthomonadin biosynthesis of Xanthomonas campestris pv. campestris
por: Yu, Yonghong, et al.
Publicado: (2019)

Escherichia coli FabG 3-ketoacyl-ACP reductase proteins lacking the assigned catalytic triad residues are active enzymes
por: Hu, Zhe, et al.
Publicado: (2021)

Shewanella oneidensis FabB: A β-ketoacyl-ACP Synthase That Works with C16:1-ACP
por: Luo, Qixia, et al.
Publicado: (2016)

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics
por: Kaplan, Nachum, et al.
Publicado: (2013)

Ligand‐ and Structure‐Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence
por: Kronenberger, Thales, et al.
Publicado: (2019)

Expression, purification and preliminary crystallographic analysis of the Toxoplasma gondii enoyl reductase
por: Muench, Stephen P., et al.
Publicado: (2006)

An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections
por: Parker, Erica N., et al.
Publicado: (2022)

A novel circuit overrides Adr 1p control during expression of Saccharomyces cerevisiae 2-trans-enoyl-ACP reductase Etr 1p of mitochondrial type 2 fatty acid synthase
por: Gurvitz, Aner
Publicado: (2009)

Correction to “An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections”
por: Parker, Erica N., et al.
Publicado: (2022)

Evaluation of Enoyl-Acyl Carrier Protein Reductase Inhibitors as Pseudomonas aeruginosa Quorum-Quenching Reagents
por: Yang, Liang, et al.
Publicado: (2010)

Synthesis, Molecular Docking Study, and Biological Evaluation of New 4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N’-(2-(substituted)acetyl)benzohydrazides as Dual Enoyl ACP Reductase and DHFR Enzyme Inhibitors
por: Mahnashi, Mater H., et al.
Publicado: (2023)

Review of Platensimycin and Platencin: Inhibitors of β-Ketoacyl-acyl Carrier Protein (ACP) Synthase III (FabH)
por: Shang, Ruofeng, et al.
Publicado: (2015)

The biodistribution of 5-[(18)F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography
por: Zhang, Zhuo, et al.
Publicado: (2017)

The Two Functional Enoyl-Acyl Carrier Protein Reductases of Enterococcus faecalis Do Not Mediate Triclosan Resistance
por: Zhu, Lei, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6dqbi61vve5r8f9uihr2n6gqi9